1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
(
- Contribution to journal › Article
-
Mark
Immune gene expression and response to chemotherapy in advanced breast cancer
(
- Contribution to journal › Article
- 2017
-
Mark
PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients
(
- Contribution to journal › Article
- 2016
-
Mark
Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer.
(
- Contribution to journal › Article
- 2015
-
Mark
Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer
(
- Contribution to journal › Published meeting abstract
- 2014
-
Mark
Molecular profiling of male breast cancer - Lost in translation?
(
- Contribution to journal › Scientific review
-
Mark
Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer
(
- Contribution to journal › Article
- 2013
-
Mark
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy
(
- Contribution to journal › Article
- 2011
-
Mark
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
(
- Contribution to journal › Article